Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Full data from mirvetuximab’s Soraya study make investors nervous as readout of the Mirasol confirmatory trial looms.
In a battle of anti-folate receptor α projects STRO-002 outperforms mirvetuximab, but Sutro investors are not celebrating.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.